Skip to content
Recovery & Performance PeptidesRecovery research and practical context
Source comparison

How Does Hexarelin Work: Research Compound Comparison

The table below compares Hexarelin work mechanisms against other growth hormone secretagogues used in research settings, highlighting receptor targets, primary signaling pathways, and desensitization kinetics. Hexarelin GHS-R1a 600–800% increase CD36 (cardiopr

This comparison does not assign a generated winner or score.

  • The table below compares Hexarelin work mechanisms against other growth hormone secretagogues used in research settings, highlighting receptor targets, primary signaling pathways, and desensitization kinetics.
  • Hexarelin
  • GHS-R1a
  • 600–800% increase
  • CD36 (cardioprotective), moderate prolactin/cortisol
  • 4–6 weeks daily dosing
  • Dual CD36/GHS-R1a activation. Cardioprotection independent of GH signaling
  • GHRP-2
  • 400–600% increase
  • Moderate prolactin, minimal CD36
  • 8–10 weeks daily dosing
  • Balanced GH stimulation with lower desensitization rate than Hexarelin
  • Ipamorelin
  • 300–500% increase
  • Minimal. Highly selective
  • 12+ weeks daily dosing
  • Cleanest receptor profile. No appetite, prolactin, or cortisol stimulation
  • MK-677
  • 200–400% sustained
  • Moderate appetite stimulation
  • Minimal (continuous dosing)
  • Oral bioavailability, 24-hour half-life. Sustained rather than pulsatile GH elevation
  • CJC-1295 No DAC
  • GHRH receptor
  • 200–300% increase (amplifies natural pulses)
  • None
  • Minimal
  • GHRH analog. Amplifies endogenous GH pulses rather than creating artificial peaks
  • Bottom Line: Hexarelin work produces the largest acute GH response and is the only GHS-R1a agonist with demonstrated cardioprotective signaling through CD36 receptors. For short-term or cyclic research protocols requiring maximal GH stimulation, Hexarelin is unmatched. For sustained studies exceeding 6–8 weeks, Ipamorelin or MK-677 provide more stable long-term GH elevation without tachyphylaxis. Researchers studying cardiac ischemia or heart failure models should prioritize Hexarelin for its CD36-mediated anti-apoptotic effects, which persist independently of GH receptor activation.